Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week open-label study of alfuzosin in children with neuropathic voiding dysfunction
2007-000983-26Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alfuzosin in neurogenic bladder and Micturition disorder, sponsored by Sanofi. Primary endpoint: Change in grade of hydronephrosis. Started Oct 2007; status: completed.
02
Drugs
alfuzosin
03
Conditions
neurogenic bladderMicturition disorder
Beyond the preview
Go deeper on 2007-000983-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000983-26.